Long-Term Maintenance of Vision and Resolution of Vitelliform Lesions with Systemic Phosphodiesterase 5/6 Treatment (Sildenafil)

Main Article Content

D. Jackson Coleman Winston Lee, MS Vivienne C. Greenstein, PhD Suzanne Daly, BSN Stephen H. Tsang, MD, PhD

Abstract

Background: Adult vitelliform macular dystrophy results in loss of central vision.  The use of systemic sildenafil has been proven to increase choroidal blood flow.  This is a report of a favorable long-term treatment outcome using systemic sildenafil for a patient with adult onset vitelliform macular dystrophy.


Case Presentation: A 55-year-old woman presenting with bilateral subretinal vitelliform lesions was initially assessed by full-field electroretinogram, electro-oculogram and direct sequencing of the RDS/PRPH2 and BEST1 genes.  Best-corrected visual acuity, spectral domain-optical coherence tomography and color fundus photography were obtained and analyzed over a 5-year treatment course which included bevacizumab (Avastin) injections in the right eye and left eye and subsequent ranibizumab (Lucentis) treatments in the left eye.  Lipid resolution in the right eye was seen with bevacizumab after two months of treatment, while the left eye was unresponsive to eight subsequent injections of bevacizumab, followed by ranibizumab over a period of twenty months.  Off-label systemic sildenafil was started following the 20-month course of intravitreal injections.  There were both measured and patient-reported improvements in the left eye at two months after the initiation of sildenafil.


Conclusions: These data appear to support our hypothesis that systemic phosphodiesterase (PDE)-5 and -6 inhibitors may facilitate the removal of lipid and waste from the subretinal space by increasing perfusion in patients with vitelliform lesions and aid in maintaining and/or recovering photoreceptor function.

Keywords: vitelliform, macular dystrophy, sildenafil, microperimetry

Article Details

How to Cite
COLEMAN, D. Jackson et al. Long-Term Maintenance of Vision and Resolution of Vitelliform Lesions with Systemic Phosphodiesterase 5/6 Treatment (Sildenafil). Medical Research Archives, [S.l.], v. 9, n. 11, nov. 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2459>. Date accessed: 17 apr. 2024. doi: https://doi.org/10.18103/mra.v9i11.2459.
Section
Case Reports

References

1. Adult-onset vitelliform macular dystrophy/Genetic and Rare Diseases Information Center (GARD) [database on the Internet]. NCATS Progam. [cited 1/5/2017].
2. Puche N, Querques G, Benhamou N, Tick S, Mimoun G, Martinelli D, et al. Highresolution spectral domain optical coherence tomography features in adult onset foveomacular vitelliform dystrophy. Br J Ophthalmol. 2010 Sep;94(9):1190-6. PubMed PMID: 20576764.
3. Wells J, Wroblewski J, Keen J, Inglehearn C, Jubb C, Eckstein A, et al. Mutations in the human retinal degeneration slow (RDS) gene can cause either retinitis pigmentosa or macular dystrophy. Nat Genet. 1993 Mar;3(3):213-8. PubMed PMID: 8485576.
4. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, et al. Identification of the gene responsible for Best macular dystrophy. Nat Genet. 1998 Jul;19(3):241-7. PubMed PMID: 9662395.
5. Gass JD. A clinicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc. 1974;72:139-56. PubMed PMID: 4142662. Pubmed Central PMCID: PMC1311393.
6. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006 Apr;113(4):633 e1-4. PubMed PMID: 16483659.
7. Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1981-9. PubMed PMID: 10845625.
8. Benhamou N, Souied EH, Zolf R, Coscas F, Coscas G, Soubrane G. Adult-onset foveomacular vitelliform dystrophy: a study by optical coherence tomography. Am J Ophthalmol. 2003 Mar;135(3):362-7. PubMed PMID: 12614755.
9. Da Pozzo S, Parodi MB, Toto L, Ravalico G. Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica. 2001 Nov-Dec;215(6):412-4. PubMed PMID: 11741106.
10. Coleman DJ, Silverman RH, Rondeau MJ, Lloyd HO, Khanifar AA, Chan RV. Age related macular degeneration: choroidal ischaemia? Br J Ophthalmol. 2013 Aug;97(8):1020-3. PubMed PMID: 23740965. Pubmed Central PMCID: PMC3717761.
11. Kim DY, Silverman RH, Chan RV, Khanifar AA, Rondeau M, Lloyd H, et al.
Measurement of choroidal perfusion and thickness following systemic sildenafil (Viagra((R)) ). Acta Ophthalmol. 2013 Mar;91(2):183-8. PubMed PMID: 22974308. Pubmed Central PMCID: PMC3528845.
12. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina. 2011 Feb;31(2):332-5. PubMed PMID: 20975620.
13. Jung JJ, Freund KB. Long-term follow-up of outer retinal tubulation documented by eyetracked and en face spectral-domain optical coherence tomography. Arch Ophthalmol. 2012 Dec;130(12):1618-9. PubMed PMID: 23229712.
14. Litts KM, Ach T, Hammack KM, Sloan KR, Zhang Y, Freund KB, et al. Quantitative
Analysis of Outer Retinal Tubulation in Age-Related Macular Degeneration From SpectralDomain Optical Coherence Tomography and Histology. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2647-56. PubMed PMID: 27177321. Pubmed Central PMCID: PMC4868096.
15. Schaal KB, Freund KB, Litts KM, Zhang Y, Messinger JD, Curcio CA. Outer retinal tubulation in advanced age-related macular degeneration: Optical Coherence Tomographic Findings Correspond to Histology. Retina. 2015 Jul;35(7):1339-50. PubMed PMID: 25635579. Pubmed Central PMCID: PMC4478232.
16. Marmor MF, Brigell MG, McCulloch DL, Westall CA, Bach M, International Society for Clinical Electrophysiology of V. ISCEV standard for clinical electro-oculography (2010 update). Doc Ophthalmol. 2011 Feb;122(1):1-7. PubMed PMID: 21298321.
17. Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH. Highdefinition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol. 2008 Oct;146(4):501-7. PubMed PMID: 18619572.
18. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002 Sep;134(3):411-31. PubMed PMID: 12208254.
19. Flower RW, Fryczkowski AW, McLeod DS. Variability in choriocapillaris blood flow distribution. Invest Ophthalmol Vis Sci. 1995 Jun;36(7):1247-58. PubMed PMID: 7775102.
20. Coleman DJ, Lee W, Chang S, Silverman RH, Lloyd HO, Daly S, et al. Treatment of Macular Degeneration with Sildenafil: Results of a Two-Year Trial. Ophthalmologica. 2018;240(1):45-54. PubMed PMID: 29694963.
21. Breazzano MP, Coleman DJ, Chen RWS, Chang S, Daly S, Tsang SH. Prospective impact of sildenafil on chronic cEntral serous chorioretinopathy: PISCES Trial. Ophthalmol Retina. 2020 Nov;4(11):1119-1123. PubMed PMID: 32525054
22. Coleman DJ, Lee W, Daly S, Breazzano MP, Sparrow J, Tsang SH. Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil). Am J Ophthalmol Case Rep. 2020 Dec 3;21:100998. PubMed PMID: 33364520.